Spain: Research Cooperation Almirall and Evotec Collaborate for Dermatological Diseases

Editor: Ahlam Rais

Under the agreement, both the firms will carry out research work to develop first-in-class therapies to treat dermatological diseases.

Related Company

The collaboration combines Evotec’s cutting-edge drug discovery and pre-clinical development platforms with Almirall’s leading expertise in dermatology diseases.
The collaboration combines Evotec’s cutting-edge drug discovery and pre-clinical development platforms with Almirall’s leading expertise in dermatology diseases.
(Source: Deposit Photos)

Barcelona/Spain – Almirall and Evotec have recently announced that they have entered into a research collaboration to discover and develop the first-in-class therapeutics through a novel approach to disrupt cell signaling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis.

The collaboration combines Evotec’s cutting-edge drug discovery and pre-clinical development platforms with Almirall’s leading expertise in dermatology diseases. Under the terms of the agreement, Evotec will receive research funding and may be eligible to receive discovery, pre-clinical, clinical and sales milestone payments as well as tiered royalties.

(ID:45499450)